Search | Clinical Trials Finder

Conditions: Growth Hormone Disorder, Growth Hormone Deficiency in Children
Interventions: somatropin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 21
States / cities: Los Angeles, California • Wilmington, Delaware • Washington D.C., District of Columbia + 15 more

Conditions: Growth Hormone Deficiency (GHD)
Interventions: LUM-201, Matched Placebo (Capsules); Drug · Other
Lead sponsor: Lumos Pharma; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 30
States / cities: Birmingham, Alabama • Madera, California • Orange, California + 27 more

Conditions: Growth Hormone Disorder, Pituitary Dwarfism
Interventions: somatropin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 3 Years to 13 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 27
States / cities: Los Angeles, California • San Diego, California • Stanford, California + 23 more

Conditions: Growth Failure, X-linked Severe Combined Immunodeficiency (XSCID), Growth Hormone Resistence
Interventions: Increlex; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 20 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Growth Hormone Disorder, Adult Growth Hormone Deficiency
Interventions: somapacitan, somatropin, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 23 Years to 79 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 23 more

Conditions: Hypotension, Respiratory Failure
Interventions: Blood draws; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 12 Months to 18 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: TBI (Traumatic Brain Injury), Concussion, Brain, Sport Injury, Anterior Pituitary Hyposecretion Syndrome, Hypopituitarism, Growth Hormone Deficiency
Interventions: Growth Hormone, Placebo; Biological · Other
Lead sponsor: Center for Neurological Studies; Other
Eligibility: 18 Years to 76 Years · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Dearborn, Michigan

Conditions: Growth Hormone Deficiency
Interventions: ALRN-5281 0.015 mg/kg, ALRN-5281 0.05 mg/kg, ALRN-5281 0.15 mg/kg, Placebo 0.015 mg/kg, Placebo 0.05mg/kg, Placebo 0.15mg/kg; Drug
Lead sponsor: Aileron Therapeutics, Inc.; Industry
Eligibility: 20 Years to 50 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Growth Hormone Disorder, Growth Hormone Deficiency in Children
Interventions: somapacitan, Norditropin® FlexPro® pen; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 2 Years to 10 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 27
States / cities: Birmingham, Alabama • Los Angeles, California • Madera, California + 18 more

Conditions: Obesity, Growth Hormone
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 149 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pediatric Growth Hormone Deficiency
Interventions: MOD-4023, Somatropin; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 18
States / cities: Orange, California • Aurora, Colorado • Centennial, Colorado + 15 more

Conditions: Vitamin D Deficiency
Interventions: High Dose Vitamin D3, Low Dose Vitamin D3, Placebo; Dietary Supplement
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Up to 75 Years · Female only
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hypophosphatemic Rickets, X-Linked Dominant
Interventions: Cinacalcet; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 5 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Kidney Failure, Chronic, Chronic Kidney Disease-Mineral and Bone Disorder
Interventions: Oral calcitriol with cinacalcet rescue, IV activated vitamin D; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
Interventions: Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector; Combination Product
Lead sponsor: Ascendis Pharma A/S; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 19
States / cities: Palo Alto, California • Sacramento, California • Aurora, Colorado + 15 more

Conditions: Menopause Surgical, Estrogen Deficiency, Adiposity, Follicle-Stimulating Hormone Deficiency, Hormone Deficiency
Interventions: 'Surgical Menopause' Group, 'Drug-Induced Menopause' Group; Procedure · Drug
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 50 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Growth Hormone Deficiency
Interventions: No intervention; Other
Lead sponsor: Ascendis Pharma Endocrinology Division A/S; Industry
Eligibility: Not listed
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 27
States / cities: Phoenix, Arizona • Orange, California • Sacramento, California + 23 more

Conditions: HIV Infections
Interventions: Somatropin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 4 Years to 13 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 18
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 13 more

Conditions: Hypopituitarism
Interventions: Human Growth Hormone (1-134), Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Growth Hormone Deficiency, Traumatic Brain Injury
Interventions: Recombinant human growth hormone; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 21 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2015
U.S. locations: 2
States / cities: Galveston, Texas

Conditions: Growth Hormone Disorder, Adult Growth Hormone Deficiency, Healthy
Interventions: somatropin, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 20 Years to 50 Years · Male only
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: HIV Infections, Lipodystrophy
Interventions: TH9507; Drug
Lead sponsor: Theratechnologies; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 35
States / cities: Los Angeles, California • Palm Springs, California • San Diego, California + 25 more

Conditions: Infant, Very Low Birth Weight, Calcium Deficiency, Vitamin D Deficiency
Interventions: 400 IU Cholecalciferol- Vitamin D Daily; Dietary Supplement
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 1 Day to 3 Days
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Charleston, South Carolina

Conditions: Menopause, Aging
Interventions: KUVAN, Placebo, Cetrotide, Climara, Placebo transdermal patch; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency

Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency

Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children

Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.

Thyroid Hormones in Critically Ill Children

Growth Hormone Replacement Therapy for Retried Professional Football Players

Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency

Prevalence and Cardiovascular Effects of Growth Hormone Deficiency in Abdominal Obesity

Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

Treatment of Vitamin D Insufficiency

Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets

DePTH: De-emphasize PTH

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

Understanding the Roles of Hormones in Adipocyte Remodeling Following Menopause

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

Growth Hormone Treatment of Children With HIV-Associated Growth Failure

Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency

Anterior Pituitary Hormone Replacement in Traumatic Brain Injury

A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin

TH9507 in Patients With HIV-Associated Lipodystrophy

Identifying Vitamin D Deficiency in Very Low Birth Weight Infant (VLBW) Infants Part 2

Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women